CLINICAL TRIALS SHARED RESOURCE
临床试验共享资源
基本信息
- 批准号:6990192
- 负责人:
- 金额:$ 23.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-28 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The Clinical Trials Shared Resource (CTSR) facilitates and enhances the efficiency of clinical trial conduct among the many elements of the VICC. It provides critical human resources and benefits including training for inexperienced and experienced investigators in the preparation of protocols for regulatory review and budget development. The major areas of responsibility of the CTSR include support for all regulatory requirements such as IRB submissions and annual reporting, IND submissions and annual reporting, as well as assistance with protocol submissions to the Scientific Review Committee, the GCRC and the NCI; assistance with budget development and contract negotiations and resolution of problems pertaining to resource allocations; data management for all SRC-approved clinical trials; and provision of research nursing support as required by the clinical protocol. In order to meet these goals, CTSR services are grouped into three categories: Shared Resource Services, Data Management Services, and Research Nursing Services. In sum, the primary mission of the CTSR is to assist VICC investigators in developing, activating, and completing scientifically meritorious clinical trials in an efficient, cost-effective, and technically sound manner. Dr. Jeffrey Sosman is the Medical Director of the CTSR. He is assisted by Kelly Willenberg, R. N., the Clinical Director, who is responsible for the day-to-day operations of the CTSR and David Browning, who handles protocol activation and implementation. A multitude of other staff provides support for the widely
varying functions of the Clinical Trials Shared Resource.
临床试验共享资源 (CTSR) 促进并提高了 VICC 众多要素中临床试验实施的效率。它提供了关键的人力资源和福利,包括为缺乏经验和经验丰富的研究人员提供培训,以制定监管审查和预算制定方案。 CTSR 的主要职责领域包括支持所有监管要求,例如 IRB 提交和年度报告、IND 提交和年度报告,以及协助向科学审查委员会、GCRC 和 NCI 提交方案;协助预算制定和合同谈判以及解决与资源分配有关的问题;所有 SRC 批准的临床试验的数据管理;并根据临床方案的要求提供研究护理支持。为了实现这些目标,CTSR 服务分为三类:共享资源服务、数据管理服务和研究护理服务。总之,CTSR 的主要任务是协助 VICC 研究人员以高效、经济且技术可靠的方式开发、启动和完成具有科学价值的临床试验。 Jeffrey Sosman 博士是 CTSR 的医疗主任。他由负责 CTSR 日常运营的临床主任 Kelly Willenberg, R. N. 和负责方案激活和实施的 David Browning 协助。许多其他工作人员为广泛的工作提供支持
临床试验共享资源的不同功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey A Sosman其他文献
Biological drug duo delivers one-two tumor punch
生物药物组合打出一记一二连击肿瘤
- DOI:
10.1038/nm0603-649 - 发表时间:
2003-06-01 - 期刊:
- 影响因子:50.000
- 作者:
Jeffrey A Sosman;James W Mier - 通讯作者:
James W Mier
Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1
- DOI:
10.1186/2051-1426-1-s1-o12 - 发表时间:
2013-11-01 - 期刊:
- 影响因子:10.600
- 作者:
Holbrook Kohrt;Marcin Kowanetz;Scott Gettinger;John Powderly;Hartmut Koeppen;Jeffrey A Sosman;Cristina Cruz;Yuanyuan Xiao;Ahmad Mokatrin;Gregg Fine;Daniel S Chen;F Stephen Hodi - 通讯作者:
F Stephen Hodi
Jeffrey A Sosman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey A Sosman', 18)}}的其他基金
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity
免疫检查点抑制剂治疗引起的结肠毒性的路径引导治疗
- 批准号:
10752985 - 财政年份:2023
- 资助金额:
$ 23.21万 - 项目类别:
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
(IND 102,133) 抑制极光激酶 A 治疗黑色素瘤
- 批准号:
8142146 - 财政年份:2010
- 资助金额:
$ 23.21万 - 项目类别:
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
(IND 102,133) 抑制极光激酶 A 治疗黑色素瘤
- 批准号:
7771855 - 财政年份:2010
- 资助金额:
$ 23.21万 - 项目类别:
PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C
PHI-0241-蛋白酶体抑制剂 PS-341 的 I/II 期临床试验
- 批准号:
7605557 - 财政年份:2006
- 资助金额:
$ 23.21万 - 项目类别:
PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB
贝伐珠单抗、埃洛替尼、伊马替尼的 I/II 期试验
- 批准号:
7731408 - 财政年份:2006
- 资助金额:
$ 23.21万 - 项目类别:
PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB
贝伐珠单抗、埃洛替尼、伊马替尼的 I/II 期试验
- 批准号:
7605583 - 财政年份:2006
- 资助金额:
$ 23.21万 - 项目类别:
PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C
PHI-0241-蛋白酶体抑制剂 PS-341 的 I/II 期临床试验
- 批准号:
7731382 - 财政年份:2006
- 资助金额:
$ 23.21万 - 项目类别:
PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C
PHI-0241-蛋白酶体抑制剂 PS-341 的 I/II 期临床试验
- 批准号:
7375618 - 财政年份:2005
- 资助金额:
$ 23.21万 - 项目类别:
PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB
贝伐珠单抗、埃洛替尼、伊马替尼的 I/II 期试验
- 批准号:
7375664 - 财政年份:2005
- 资助金额:
$ 23.21万 - 项目类别:
Overcoming DC defects in cancer patients by VEGF trap
通过 VEGF trap 克服癌症患者 DC 缺陷
- 批准号:
7033492 - 财政年份:2004
- 资助金额:
$ 23.21万 - 项目类别:
相似海外基金
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)
统计和数据管理中心(SDMC)、艾滋病临床试验组(ACTG)
- 批准号:
10200227 - 财政年份:2020
- 资助金额:
$ 23.21万 - 项目类别:
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)
统计和数据管理中心(SDMC)、艾滋病临床试验组(ACTG)
- 批准号:
10316777 - 财政年份:2020
- 资助金额:
$ 23.21万 - 项目类别:
Powering clinical trials research through a secure and integrated data management platform
通过安全、集成的数据管理平台为临床试验研究提供动力
- 批准号:
488912-2015 - 财政年份:2017
- 资助金额:
$ 23.21万 - 项目类别:
Collaborative Research and Development Grants
Powering clinical trials research through a secure and integrated data management platform
通过安全、集成的数据管理平台为临床试验研究提供动力
- 批准号:
488912-2015 - 财政年份:2016
- 资助金额:
$ 23.21万 - 项目类别:
Collaborative Research and Development Grants
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Statistics and Data Management Core
加拿大癌症试验组 - 加拿大合作临床试验网络:统计和数据管理核心
- 批准号:
10361221 - 财政年份:2014
- 资助金额:
$ 23.21万 - 项目类别:
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Statistics and Data Management Core
加拿大癌症试验组 - 加拿大合作临床试验网络:统计和数据管理核心
- 批准号:
10600863 - 财政年份:2014
- 资助金额:
$ 23.21万 - 项目类别:
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Statistics and Data Management Core
加拿大癌症试验组 - 加拿大合作临床试验网络:统计和数据管理核心
- 批准号:
10116971 - 财政年份:2014
- 资助金额:
$ 23.21万 - 项目类别:
Efficient Approaches of Case Registration and Data management in Clinical Trials
临床试验中病例登记和数据管理的有效方法
- 批准号:
20590538 - 财政年份:2008
- 资助金额:
$ 23.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Core--Clinical Trials, Data Management and Statistics
核心--临床试验、数据管理和统计
- 批准号:
7422297 - 财政年份:2007
- 资助金额:
$ 23.21万 - 项目类别:
Statistical and Data Management Center for the AIDS Clinical Trials Group
艾滋病临床试验组统计和数据管理中心
- 批准号:
8645801 - 财政年份:2006
- 资助金额:
$ 23.21万 - 项目类别: